Oryzon Genomics Croissance future
Future contrôle des critères 5/6
Oryzon Genomics is forecast to grow earnings and revenue by 78.8% and 66.1% per annum respectively. EPS is expected to grow by 77% per annum. Return on equity is forecast to be -3.3% in 3 years.
Informations clés
78.8%
Taux de croissance des bénéfices
77.0%
Taux de croissance du BPA
Biotechs croissance des bénéfices | 36.4% |
Taux de croissance des recettes | 66.1% |
Rendement futur des capitaux propres | -3.3% |
Couverture par les analystes | Low |
Dernière mise à jour | 31 Oct 2024 |
Mises à jour récentes de la croissance future
Recent updates
Growth Investors: Industry Analysts Just Upgraded Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts By 54%
Oct 03Oryzon Genomics S.A. (BME:ORY) Screens Well But There Might Be A Catch
Jun 09Is Oryzon Genomics (BME:ORY) Using Too Much Debt?
Apr 04Industry Analysts Just Made A Dazzling Upgrade To Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts
Jul 24Is Oryzon Genomics (BME:ORY) Weighed On By Its Debt Load?
May 01Oryzon Genomics (BME:ORY) Has Debt But No Earnings; Should You Worry?
Feb 26If You Had Bought Oryzon Genomics (BME:ORY) Shares A Year Ago You'd Have Earned 18% Returns
Jan 04Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 8 | -7 | -20 | N/A | 3 |
12/31/2025 | 5 | -7 | -17 | N/A | 3 |
12/31/2024 | 9 | -4 | -13 | N/A | 2 |
9/30/2024 | 16 | -5 | N/A | N/A | N/A |
6/30/2024 | 12 | -4 | -14 | -2 | N/A |
3/31/2024 | 15 | -3 | N/A | N/A | N/A |
12/31/2023 | 16 | -4 | -17 | -1 | N/A |
9/30/2023 | 17 | -4 | N/A | N/A | N/A |
6/30/2023 | 17 | -4 | -21 | -3 | N/A |
3/31/2023 | 17 | -5 | N/A | N/A | N/A |
12/31/2022 | 17 | -5 | -17 | -2 | N/A |
9/30/2022 | 10 | -3 | N/A | N/A | N/A |
6/30/2022 | 14 | -5 | -15 | -3 | N/A |
3/31/2022 | 12 | -5 | N/A | N/A | N/A |
12/31/2021 | 12 | -5 | -18 | -4 | N/A |
9/30/2021 | 11 | -4 | N/A | N/A | N/A |
6/30/2021 | 10 | -4 | -17 | -4 | N/A |
3/31/2021 | 7 | -5 | N/A | N/A | N/A |
12/31/2020 | 12 | -4 | -17 | -6 | N/A |
9/30/2020 | 12 | -4 | N/A | N/A | N/A |
6/30/2020 | 13 | -4 | -16 | -4 | N/A |
3/31/2020 | 13 | -4 | N/A | N/A | N/A |
12/31/2019 | 12 | -4 | -15 | -4 | N/A |
9/30/2019 | 10 | -4 | N/A | N/A | N/A |
6/30/2019 | 9 | -4 | -11 | -3 | N/A |
3/31/2019 | 8 | -2 | N/A | N/A | N/A |
12/31/2018 | 8 | -1 | -9 | -1 | N/A |
9/30/2018 | 7 | -2 | N/A | N/A | N/A |
6/30/2018 | 6 | -2 | N/A | -5 | N/A |
3/31/2018 | 6 | -6 | N/A | N/A | N/A |
12/31/2017 | 5 | -6 | N/A | -6 | N/A |
9/30/2017 | 6 | -6 | N/A | N/A | N/A |
6/30/2017 | 6 | -6 | N/A | -4 | N/A |
3/31/2017 | 5 | -6 | N/A | N/A | N/A |
12/31/2016 | 5 | -6 | N/A | -5 | N/A |
9/30/2016 | 6 | -5 | N/A | N/A | N/A |
6/30/2016 | 6 | -4 | N/A | -1 | N/A |
3/31/2016 | 8 | -1 | N/A | N/A | N/A |
12/31/2015 | 8 | -1 | N/A | 1 | N/A |
9/30/2015 | 8 | -1 | N/A | N/A | N/A |
6/30/2015 | 7 | -1 | N/A | N/A | N/A |
3/31/2015 | 11 | 2 | N/A | N/A | N/A |
12/31/2014 | 19 | 8 | N/A | 15 | N/A |
12/31/2013 | 3 | -3 | N/A | N/A | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: ORY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Bénéfices vs marché: ORY is forecast to become profitable over the next 3 years, which is considered above average market growth.
Croissance élevée des bénéfices: ORY is expected to become profitable in the next 3 years.
Chiffre d'affaires vs marché: ORY's revenue (66.1% per year) is forecast to grow faster than the Spanish market (5% per year).
Croissance élevée des revenus: ORY's revenue (66.1% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: ORY is forecast to be unprofitable in 3 years.